Cargando…
Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study
BACKGROUND: Reasons for the variation in reported treatment outcomes from antiretroviral therapy (ART) programmes in developing countries are not clearly defined. METHODS: Among ART-naïve individuals in a workplace ART programme in South Africa we determined virological outcomes at 12 months, and ri...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494994/ https://www.ncbi.nlm.nih.gov/pubmed/18631397 http://dx.doi.org/10.1186/1471-2334-8-93 |
_version_ | 1782158257041702912 |
---|---|
author | Fielding, Katherine L Charalambous, Salome Stenson, Amy L Pemba, Lindiwe F Martin, Des J Wood, Robin Churchyard, Gavin J Grant, Alison D |
author_facet | Fielding, Katherine L Charalambous, Salome Stenson, Amy L Pemba, Lindiwe F Martin, Des J Wood, Robin Churchyard, Gavin J Grant, Alison D |
author_sort | Fielding, Katherine L |
collection | PubMed |
description | BACKGROUND: Reasons for the variation in reported treatment outcomes from antiretroviral therapy (ART) programmes in developing countries are not clearly defined. METHODS: Among ART-naïve individuals in a workplace ART programme in South Africa we determined virological outcomes at 12 months, and risk factors for suboptimal virological outcome, defined as plasma HIV-1 viral load >= 400 copies/ml. RESULTS: Among 1760 individuals starting ART before July 2004, 1172 were in follow-up at 12 months of whom 953 (81%) had a viral load measurement (median age 41 yrs, 96% male, median baseline CD4 count 156 × 10(6)/l). 71% (681/953) had viral load < 400 copies/ml at 12 months. In a multivariable analysis, independent predictors of suboptimal virological outcome at 12 months were <1 log decrease in viral load at six weeks (odds ratio [OR] 4.71, 95% confidence interval [CI] 2.56–8.68), viral load at baseline (OR 3.63 [95% CI 1.88–7.00] and OR 3.54 [95% CI 1.79–7.00] for 10,001–100,000 and >100,000 compared to <= 10,000 copies/ml, respectively), adherence at six weeks (OR 3.50 [95% CI 1.92–6.35]), WHO stage (OR 2.08 [95% CI 1.28–3.34] and OR 2.03 [95% CI 1.14–3.62] for stage 3 and 4 compared to stage 1–2, respectively) and site of ART delivery. Site of delivery remained an independent risk factor even after adjustment for individual level factors. At 6 weeks, of 719 patients with self-reported adherence and viral load, 72 (10%) reported 100% adherence but had <1 log decrease in viral load; conversely, 60 (8%) reported <100% adherence but had >= 1 log decrease in viral load. CONCLUSION: Virological response at six weeks after ART start was the strongest predictor of suboptimal virological outcome at 12 months, and may identify individuals who need interventions such as additional adherence support. Self reported adherence was less strongly associated but identified different patients compared with viral load at 6 weeks. Site of delivery had an important influence on virological outcomes; factors at the health system level which influence outcome need further investigation to guide development of effective ART programmes. |
format | Text |
id | pubmed-2494994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-24949942008-08-05 Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study Fielding, Katherine L Charalambous, Salome Stenson, Amy L Pemba, Lindiwe F Martin, Des J Wood, Robin Churchyard, Gavin J Grant, Alison D BMC Infect Dis Research Article BACKGROUND: Reasons for the variation in reported treatment outcomes from antiretroviral therapy (ART) programmes in developing countries are not clearly defined. METHODS: Among ART-naïve individuals in a workplace ART programme in South Africa we determined virological outcomes at 12 months, and risk factors for suboptimal virological outcome, defined as plasma HIV-1 viral load >= 400 copies/ml. RESULTS: Among 1760 individuals starting ART before July 2004, 1172 were in follow-up at 12 months of whom 953 (81%) had a viral load measurement (median age 41 yrs, 96% male, median baseline CD4 count 156 × 10(6)/l). 71% (681/953) had viral load < 400 copies/ml at 12 months. In a multivariable analysis, independent predictors of suboptimal virological outcome at 12 months were <1 log decrease in viral load at six weeks (odds ratio [OR] 4.71, 95% confidence interval [CI] 2.56–8.68), viral load at baseline (OR 3.63 [95% CI 1.88–7.00] and OR 3.54 [95% CI 1.79–7.00] for 10,001–100,000 and >100,000 compared to <= 10,000 copies/ml, respectively), adherence at six weeks (OR 3.50 [95% CI 1.92–6.35]), WHO stage (OR 2.08 [95% CI 1.28–3.34] and OR 2.03 [95% CI 1.14–3.62] for stage 3 and 4 compared to stage 1–2, respectively) and site of ART delivery. Site of delivery remained an independent risk factor even after adjustment for individual level factors. At 6 weeks, of 719 patients with self-reported adherence and viral load, 72 (10%) reported 100% adherence but had <1 log decrease in viral load; conversely, 60 (8%) reported <100% adherence but had >= 1 log decrease in viral load. CONCLUSION: Virological response at six weeks after ART start was the strongest predictor of suboptimal virological outcome at 12 months, and may identify individuals who need interventions such as additional adherence support. Self reported adherence was less strongly associated but identified different patients compared with viral load at 6 weeks. Site of delivery had an important influence on virological outcomes; factors at the health system level which influence outcome need further investigation to guide development of effective ART programmes. BioMed Central 2008-07-16 /pmc/articles/PMC2494994/ /pubmed/18631397 http://dx.doi.org/10.1186/1471-2334-8-93 Text en Copyright © 2008 Fielding et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Fielding, Katherine L Charalambous, Salome Stenson, Amy L Pemba, Lindiwe F Martin, Des J Wood, Robin Churchyard, Gavin J Grant, Alison D Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study |
title | Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study |
title_full | Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study |
title_fullStr | Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study |
title_full_unstemmed | Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study |
title_short | Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study |
title_sort | risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in south africa: a cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494994/ https://www.ncbi.nlm.nih.gov/pubmed/18631397 http://dx.doi.org/10.1186/1471-2334-8-93 |
work_keys_str_mv | AT fieldingkatherinel riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy AT charalamboussalome riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy AT stensonamyl riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy AT pembalindiwef riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy AT martindesj riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy AT woodrobin riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy AT churchyardgavinj riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy AT grantalisond riskfactorsforpoorvirologicaloutcomeat12monthsinaworkplacebasedantiretroviraltherapyprogrammeinsouthafricaacohortstudy |